semaglutide frequent urination Ozempic (semaglutide) and vaginal health Ozempic: Semaglutide is a GLP-1

The proportions of participants in the semaglutide vs placebo group achieving body weight reductions of 5%, 10%, 15% and 20% were 87.0% vs 29.2%, 70.4% vs 9.2%, 47.8% vs 2.5%, and 23.3% vs 0%, respectively. I think this is an important reminder about expectation setting around weight loss: in the semaglutide group, 13% failed to lose even 5% of body weight (which is consistent with other trials,) 29.6% failed to lose 10%, 52.2% failed to lose 15%, and 76.7% failed to lose 20%

927P: effect of oral semaglutide with or without background SGLT2i in patients with T2D: subgroup analysis of PIONEER 4

GLP-1 comparison guide: Ozempic vs Wegovy vs Mounjaro vs Zepbound Knowing the differences between these medications is important, but can also be confusing

And we look forward to more results and data from you in the future meetings on how these inhibitors are affecting the course of prostate cancer down the line

Key mesolimbic reward areas, like the ventral tegmental area (VTA) and nucleus accumbens (NAc), are innervated by the GLP-1 producing neurons in the NTS, potentially allowing hindbrain GLP-1 to modulate reward behaviour directly [44]